A heterodimeric [RGD-Glu-[Cu-64-NO2A]-6-Ahx-RM2] alpha(v)beta(3)/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumors

Basit Öğe Kaydı
dc.contributor.authorDurkan, Kubra
dc.contributor.authorJiang, Zongrun
dc.contributor.authorRold, Tammy L.
dc.contributor.authorSieckman, Gary L.
dc.contributor.authorHoffman, Timothy J.
dc.contributor.authorBandari, Rajendra Prasad
dc.contributor.authorSzczodroski, Ashley F.
dc.contributor.authorLiu, Liqin
dc.contributor.authorMiao, Yubin
dc.contributor.authorReynolds, Tamila Stott
dc.contributor.authorSmith, Charles J.
dc.date.accessioned2019-10-27T22:05:23Z
dc.date.available2019-10-27T22:05:23Z
dc.date.issued2014
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: In the present study, we describe a Cu-64-radiolabeled heterodimeric peptide conjugate for dual alpha(v)beta(3)/GRPr (alpha(v)beta(3) integrin/gastrin releasing peptide receptor) targeting of the form [RGD-Glu-[Cu-64-NO2A]-6-Ahx-RM2] (RGD: the amino acid sequence [Arg-Gly-Asp], a nonregulatory peptide used for alpha(v)beta(3) integrin receptor targeting; Glu: glutamic acid; NO2A: 1,4,7-triazacyclononane-1,4-diacetic acid; 6-Ahx: 6-amino hexanoic acid; and RM2: (D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH2), an antagonist analogue of bombesin (BBN) peptide used for GRPr targeting). Methods: RGD-Glu-6Ahx-RM21 was conjugated to a NOTA (1,4,7-triazacyclononane-1,4,7-triacetic acid) complexing agent to produce [RGD-Glu-[NO2A]-6-Ahx-RM2], which was purified by reversed-phase high-performance liquid chromatography (RP-HPLC) and characterized by electrospray ionization-mass spectrometry (ESI-MS). Radiolabeling of the conjugate with Cu-64 produced [RGD-Glu-[64Cu-NO2A]-6-Ahx-RM2 in high radiochemical yield (>= 95%). In vivo behavior of the radiolabeled peptide conjugate was investigated in normal CF-1 mice and in the PC-3 human prostate cancer experimental model. Results: A competitive displacement receptor binding assay in human prostate PC-3 cells using I-125-[Tyr(4)]BBN as the radioligand showed high binding affinity of [RGD-Glu-[Cu-nat-NO2A]-6-Ahx-RM21 conjugate for the GRPr (3.09 +/- 0.34 nM). A similar assay in human, glioblastoma U87-MG cells using I-125-Echistatin as the radioligand indicated a moderate receptor-binding affinity for the alpha(v)beta(3) integrin (518 +/- 37.5 nM). In vivo studies of [RGD-Glu-[Cu-64-NO2A]-6-Ahx-RM2] showed high accumulation (4.86 +/- 1.01 %ID/g, 1 h post-intravenous injection (p.i.)) and prolonged retention (4.26 +/- 1.23 %ID/g, 24 h p.i.) of tracer in PC-3 tumor-bearing mice. Micro-positron emission tomography (microPET) molecular imaging studies produced high-quality, high contrast images in PC-3 tumor-bearing mice at 4 h p.i. Conclusions: The favorable pharmacokinetics and enhanced tumor uptake of Cu-64-NOTA-RGD-Glu-6Ahx-RM2 warrant further investigations for dual integrin and GRPr-positive tumor imaging and possible radiotherapy. (C) 2014 Elsevier Inc. All rights reserved.en_US
dc.description.sponsorshipScientific and Technological Research Council of Turkey (TUBITAK) Science Fellowships and Grant Programmes Department (BIDEB)Turkiye Bilimsel ve Teknolojik Arastirma Kurumu (TUBITAK); United States Department of Veterans' Affairs, VA Merit Bridge Funding Award Mechanismen_US
dc.description.sponsorshipThis material was the result of work supported with resources and the use of facilities at the Truman VA, Columbia, MO, 65201 and the University of Missouri School of Medicine, Columbia, MO 65211, USA. Dr. Kubra Durkan acknowledges financial support from the Scientific and Technological Research Council of Turkey (TUBITAK) Science Fellowships and Grant Programmes Department (BIDEB). This work was also funded in part by The United States Department of Veterans' Affairs, VA Merit Bridge Funding Award Mechanism.en_US
dc.identifier.doi10.1016/j.nucmedbio.2013.11.006en_US
dc.identifier.endpage139en_US
dc.identifier.issn0969-8051
dc.identifier.issn1872-9614
dc.identifier.issue2en_US
dc.identifier.pmid24480266en_US
dc.identifier.startpage133en_US
dc.identifier.urihttps://doi.org/10.1016/j.nucmedbio.2013.11.006
dc.identifier.urihttps://hdl.handle.net/11454/48392
dc.identifier.volume41en_US
dc.identifier.wosWOS:000330914300001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofNuclear Medicine and Biologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectGastrin-releasing peptideen_US
dc.subjectProstate-specific membrane antigenen_US
dc.subjectBombesinen_US
dc.subjectProstate canceren_US
dc.subjectCopper-64en_US
dc.titleA heterodimeric [RGD-Glu-[Cu-64-NO2A]-6-Ahx-RM2] alpha(v)beta(3)/GRPr-targeting antagonist radiotracer for PET imaging of prostate tumorsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu